Kalaris Therapeutics CFO listed on Form 3

Kalaris Therapeutics, Inc. lists Liisa Ann Bayko, its Chief Financial Officer, as a reporting person on Form 3.

Accepted by SEC EDGAR 07/20/2026 - 04:59 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. lists Liisa Ann Bayko, its Chief Financial Officer, as a reporting person on Form 3. The Form 3 data show no equity holdings, derivative positions, or buy or sell transactions currently reported for her in Kalaris Therapeutics securities.

Key Figures

Reported buy transactions: 0 Reported sell transactions: 0 Holding entries: 0

3 metrics

Reported buy transactions 0 Buy transactions (buyCount) in the Form 3 transactionSummary

Reported sell transactions 0 Sell transactions (sellCount) in the Form 3 transactionSummary

Holding entries 0 Non-derivative holdingEntries reported in the Form 3 data

Key Terms

Power of Attorney, Chief Financial Officer, Form 3

3 terms

Power of Attorney regulatory

"Remarks state: Exhibit 24.1 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

Chief Financial Officer financial

"Reporting person is listed with officer_title "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 3 regulatory

"Filing type is identified as Form 3 for insider reporting"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kalaris Therapeutics (KLRS) report about Liisa Ann Bayko in this Form 3?

Kalaris Therapeutics reports that Liisa Ann Bayko is a reporting person on Form 3 and serves as Chief Financial Officer. The Form 3 data show no listed equity holdings, derivative positions, or buy or sell transactions in Kalaris Therapeutics securities for her.

Are any buy or sell transactions reported for KLRS in Liisa Ann Bayko's Form 3?

No buy or sell transactions are reported; all buyCount and sellCount values are zero in the transaction summary. The Form 3 transaction list is empty, indicating no trades in Kalaris Therapeutics securities are disclosed for this reporting person.

Does the Kalaris Therapeutics (KLRS) Form 3 show any current equity holdings for Liisa Ann Bayko?

No equity holdings are shown; the Form 3 data indicate holdingEntries = 0. Together with an empty derivative summary, this means no non-derivative or derivative positions in Kalaris Therapeutics securities are reported for Liisa Ann Bayko in this Form 3.

Are any derivative securities reported for Liisa Ann Bayko in the KLRS Form 3?

No derivative securities are reported; the derivativeSummary is empty and derivativeTransactionCount is zero. This indicates no options, warrants, or other derivative positions in Kalaris Therapeutics securities are disclosed for her in this Form 3 data.

What is Liisa Ann Bayko's role at Kalaris Therapeutics (KLRS) according to the Form 3 data?

According to the Form 3 data, Liisa Ann Bayko is an officer of Kalaris Therapeutics serving as Chief Financial Officer. She is identified as a reporting person, while director and ten percent owner indicators are not marked for her in this dataset.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bayko Liisa Ann

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2026

3. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Andrew Oxtoby, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)